Neoadjuvant Treatment Options in Soft Tissue Sarcomas.

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Soft tissue sarcomas (STS) present significant heterogeneity, complicating perioperative treatment selection.
• Locally advanced STS often benefits from neoadjuvant therapy, which is gaining prominence.
• The range of neoadjuvant treatment modalities for STS is continuously expanding.

Purpose of the Study:

• To review available neoadjuvant treatment options for soft tissue sarcomas.
• To analyze the evidence, indications, and risks associated with each neoadjuvant modality.
• To summarize current recommendations for assessing neoadjuvant therapy response in STS.

Main Methods:

• Comprehensive literature review of neoadjuvant therapies in soft tissue sarcomas.
• Analysis of treatment modalities including radiotherapy, chemotherapy, targeted therapy, radiosensitizers, and hyperthermia.
• Evaluation of current guidelines for response assessment in neoadjuvant STS treatment.

Main Results:

• Multiple neoadjuvant options exist for STS, including radiation, chemotherapy, targeted agents, radiosensitizers, and hyperthermia, often used in combination.
• Evidence supporting each modality varies, with specific indications and associated risks needing careful consideration.
• Standardized response assessment protocols are crucial for guiding treatment decisions.

Conclusions:

• Neoadjuvant therapy is a valuable strategy for managing locally advanced soft tissue sarcomas.
• Treatment selection requires careful consideration of STS heterogeneity, modality evidence, and patient-specific factors.
• Standardized response assessment is essential for optimizing neoadjuvant treatment outcomes in STS.